Propranolol Cancer Research Results

PRO, Propranolol: Click to Expand ⟱
Features:

Propranolol — A synthetic, lipophilic, nonselective beta-adrenergic receptor antagonist (beta-blocker; PRO) that competitively inhibits β1- and β2-adrenergic receptors (ADRB1/ADRB2). It is an established prescription drug for cardiovascular and selected neurological indications, investigated for repurposing as an adjunctive anticancer agent. Its principal oncology relevance is interruption of catecholamine-driven tumor progression, inflammatory signaling, angiogenesis, invasion, and stress-associated immunosuppression. Propranolol may be particularly relevant to perioperative cancer management, angiosarcoma, and combination immunotherapy. It is not an approved anticancer treatment.

Primary mechanisms (ranked):

  1. β1/β2-adrenergic receptor blockade: Competitively inhibits epinephrine- and norepinephrine-mediated ADRB1/ADRB2 activation, reducing downstream Gs–adenylyl cyclase–cAMP–PKA signaling. This is the principal pharmacological mechanism at therapeutic exposure.
  2. Suppression of tumor invasion and metastasis: Attenuates adrenergic stimulation of epithelial–mesenchymal transition (EMT), Snail/Slug transcriptional programs, and metastasis-associated inflammatory signaling, including NF-κB and AP-1 (context-dependent).
  3. Tumor immune microenvironment modulation: Counteracts stress-associated immunosuppression, potentially improving cytotoxic T-cell and natural killer cell activity and modifying macrophage and myeloid cell recruitment and polarization (context-dependent).
  4. Antiangiogenic signaling: Reduces catecholamine-induced VEGF expression and related vascular signaling, particularly in adrenergically responsive tumors and endothelial malignancies.
  5. Inflammatory signaling inhibition: Attenuates selected adrenergically driven IL-6, NF-κB, STAT3, and related inflammatory pathways (model-dependent).
  6. Chemosensitization and immunotherapy enhancement: May improve response to selected cytotoxic agents or immune checkpoint inhibitors. Effects depend on tumor type and treatment regimen; synergy is not universal.
  7. Direct antiproliferative and proapoptotic effects: Can induce cell-cycle disruption, mitochondrial dysfunction, ROS alterations, and apoptosis in selected experimental cancer models. Some effects require concentrations above those achieved with conventional systemic dosing.

Bioavailability / PK relevance: Oral absorption is nearly complete, but extensive hepatic first-pass metabolism reduces systemic bioavailability to approximately 25%. Peak plasma concentrations generally occur within 1–4 hours. Plasma protein binding is approximately 90%, elimination half-life is approximately 3–6 hours, and metabolism involves CYP2D6, CYP1A2, CYP2C19, and conjugation pathways. Propranolol is lipophilic and crosses the blood–brain barrier. Immediate-release formulations commonly require divided dosing. Hepatic impairment and interacting medications can substantially alter exposure.

In-vitro vs systemic exposure relevance: Beta-receptor antagonism is pharmacologically achievable with standard oral doses. In contrast, direct cancer-cell cytotoxicity reported at high micromolar concentrations may exceed clinically achievable unbound systemic exposure. Total plasma concentrations are generally in the nanomolar to submicromolar range at conventional dosing, with substantial interindividual variability. Mechanistic findings involving direct mitochondrial injury, pronounced ROS generation, or membrane toxicity require concentration-specific interpretation.

Clinical evidence status: Preclinical: extensive evidence supporting adrenergic pathway modulation and antimetastatic effects. Small human studies: encouraging results in angiosarcoma and combinations with immunotherapy. RCT: Phase II randomized perioperative breast cancer trials demonstrate favorable changes in EMT, inflammatory, and immune biomarkers, but do not establish improved overall survival. Adjunct use: investigational, including perioperative treatment and combinations with chemotherapy or checkpoint inhibitors. Evidence remains insufficient for routine oncological prescribing.

Safety / clinical constraints: Major risks include bradycardia, hypotension, atrioventricular conduction impairment, fatigue, bronchospasm, and masking of hypoglycemia symptoms. Contraindications include bronchial asthma, significant bradycardia, cardiogenic shock, and specified conduction disorders. Particular caution is required with hepatic impairment, diabetes, and interacting cardiovascular medications. Abrupt discontinuation can produce clinically important cardiovascular rebound. Oncology use requires individualized clinical supervision.

Propranolol — Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ADRB1 / ADRB2 blockade ↓ β-adrenergic signaling ↓ β1/β2 signaling P Blocks catecholamine-dependent signaling Core pharmacological mechanism; therapeutically achievable receptor antagonism. Tumor relevance depends on adrenergic signaling and microenvironment.
2 cAMP / PKA / CREB ↓ (context-dependent) ↓ (context-dependent) P/R Suppresses downstream β-receptor signaling Reduces receptor-mediated cAMP production and selected downstream proliferative or stress-associated transcriptional programs.
3 EMT / Snail / Slug / Metastasis ↓ ↔ (context-dependent) G Reduces mesenchymal polarization and invasive phenotype Supported by randomized human breast cancer biomarker studies; actual reduction in distant recurrence remains unproven.
4 Immune suppression / CD8+ T cells / NK cells ↓ immune evasion ↑ antitumor immune activity (context-dependent) G May restore stress-suppressed immune surveillance Preclinical evidence and human tumor immune biomarker changes. Effects on lymphocyte populations and activity vary by model.
5 VEGF / Angiogenesis ↓ VEGF (context-dependent) ↓ angiogenic signaling (context-dependent) G Reduces catecholamine-stimulated vascular signaling Important in vascular tumors and stress-associated tumor progression. May inhibit abnormal vessel formation, but not universally.
6 NF-κB / AP-1 / IL-6 ↓ (context-dependent) ↓ inflammatory signaling (context-dependent) R/G Attenuates tumor-promoting inflammatory programs NF-κB and AP-1 modulation is supported by human breast tumor transcriptomic analysis.
7 STAT3 / TGF-β / Tumor microenvironment ↓ (context-dependent) ↔ / ↓ (context-dependent) G Reduces selected prometastatic signaling STAT3 effects observed with perioperative propranolol plus etodolac; effects cannot be attributed exclusively to propranolol.
8 Macrophages / Myeloid cells ↓ prometastatic support ↔ recruitment; ↑ antitumor polarization (context-dependent) G Remodels inflammatory and immune microenvironment May reduce stress-associated prometastatic macrophage signaling. Human biomarker studies suggest altered macrophage populations and immune infiltration.
9 Chemosensitization ↑ sensitivity (drug-dependent) ↔ / ↑ toxicity (context-dependent) G Enhances selected cytotoxic treatments Clinical pilot evidence in angiosarcoma combined with vinblastine-based metronomic chemotherapy. Other drug combinations have additive, neutral, or antagonistic effects.
10 Immune checkpoint therapy / PD-1 ↓ immune resistance (context-dependent) ↑ T-cell-mediated response (context-dependent) G Potential immunotherapy enhancement Small Phase I melanoma trial with pembrolizumab demonstrated feasibility and encouraging responses, but cannot establish added efficacy.
11 Apoptosis / Caspases / p53 family ↑ (model-dependent) ↔ / ↑ (dose-dependent) G Promotes apoptosis in susceptible tumor models Reported in selected squamous carcinoma, neuroblastoma, and vascular tumor models. Often concentration-dependent and not necessarily receptor-mediated.
12 Mitochondrial dysfunction / ROS ↑ ROS and mitochondrial stress (high concentration only) ↑ toxicity (high concentration only) R/G Potential direct cytotoxicity Secondary experimental mechanism. High-concentration findings should not be extrapolated to conventional oral dosing.
13 HIF-1α / Hypoxia-associated VEGF ↓ (model-dependent) ↔ / ↓ (context-dependent) G Possible suppression of hypoxia-associated angiogenic programs Secondary and tumor-dependent; not an established universal direct HIF-1α inhibitory mechanism.
14 Clinical Translation Constraint ↔ response variability ↓ heart rate; ↓ blood pressure; bronchospasm risk P/G Limits dosing and applicability Approximately 25% oral systemic bioavailability; extensive hepatic metabolism; high protein binding; clinical bradycardia and hypotension. Receptor blockade is achievable, whereas high-concentration direct cytotoxicity may not be.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr



Scientific Papers found: Click to Expand⟱
9113- PRO,    Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers
- Review, Var, NA
ADRB2↓, Risk↓, other⇅, TumMeta↓, Inflam↓, angioG↓, EGFR↓, COX2/PTGS2↓, VEGF↓, Hypoxia↓, BloodF⇅, RadioS↑, PD-1↓, Synergy↓,
9114- PRO,    Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent
- Review, Var, NA
ADRB2↓, TumCP↓, TumCI↓, Imm↑, angioG↓, BioAv↑, Half-Life↝, BBB↑, BioAv↝, MMP2↓, MMP9↓, VEGF↓,
9115- PRO,    Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial
- Trial, BC, NA
Dose↝, Snail↓, Slug↓, NF-kB↓, ADRB2↓, TumMeta↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Kinase & Signal Transduction(tgid=6) ⓘ

EGFR↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other⇅, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCP↓, 1,  

Migration(tgid=13) ⓘ

MMP2↓, 1,   MMP9↓, 1,   Slug↓, 1,   Snail↓, 1,   TumCI↓, 1,   TumMeta↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   Hypoxia↓, 1,   VEGF↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   Imm↑, 1,   Inflam↓, 1,   NF-kB↓, 1,   PD-1↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ADRB2↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   BioAv↝, 1,   Dose↝, 1,   Half-Life↝, 1,   RadioS↑, 1,   Synergy↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BloodF⇅, 1,   EGFR↓, 1,  

Functional Outcomes(tgid=23) ⓘ

Risk↓, 1,  
Total Targets: 28

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:512  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page